|
Pneumocystis jiroveci pneumonia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using multivariable Cox regression analyses, the outcomes of patients receiving trimethoprim/sulfamethoxazole (TMP-SMZ) or anidulafungin single therapy as an alternative treatment for PCP were investigated.
|
31622654 |
2020 |
|
Pneumocystis jiroveci pneumonia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the efficacy of combination therapy of caspofungin and TMP/SMZ (trimethoprim/sulfamethoxazole) in moderate to severe pneumocystis jirovecii pneumonia (PJP) in patients without human immunodeficiency virus infection (HIV) and the relationship between therapeutic effect and plasma (1, 3) Beta-d-Glucan (BDG) levels.
|
31442630 |
2019 |
|
Pneumocystis jiroveci pneumonia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Risk factors for PCP and prophylactic effect of trimethoprim-sulfamethoxazole (TMP-SMX) were investigated if the 1-year incidence rate (IR) of PCP in each dose group was > 0.1/100 person-years.
|
31521185 |
2019 |
|
Pneumocystis jiroveci pneumonia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The stance on PJP prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX) for non-HIV patients on corticosteroids alone (e.g., for inflammatory conditions) is unclear, with no official guidelines classifying patients by dosage, length of treatment, or preexisting conditions.
|
31763097 |
2019 |
|
Pneumocystis jiroveci pneumonia
|
0.100 |
Biomarker
|
disease |
BEFREE |
BACKGROUND Trimethoprim-sulfamethoxazole (TMP-SMX) is recommended as prophylaxis against Pneumocystis pneumonia (PCP) in renal transplant recipients.
|
31806862 |
2019 |
|
Pneumocystis jiroveci pneumonia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The standard agent for primary PCP prophylaxis is trimethoprim/sulfamethoxazole (TMP-SMX), although this agent can cause common adverse reactions, including myelosuppression and renal toxicity, that result in cessation.
|
30711257 |
2019 |
|
Pneumocystis jiroveci pneumonia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Trimethoprim-sulfamethoxazole (TMP-SMX) is the first-line agent for Pneumocystis jiroveci pneumonia (PJP) prophylaxis for solid organ transplant (SOT) recipients because of its efficacy for this indication, extended antimicrobial coverage, and favorable cost.
|
31596538 |
2019 |
|
Pneumocystis jiroveci pneumonia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lower dose SMX/TMP therapy with ≤10 mg/kg/day for TMP was as effective as higher dose therapy for the treatment of PCP and associated with lower rates of treatment modification and severe ADRs in patients with systemic rheumatic diseases.
|
30642768 |
2019 |
|
Pneumocystis jiroveci pneumonia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The prophylactic administration of TMP/SMX for PCP is recommended for RA patients who score at least 5 points with our system.
|
29664819 |
2018 |
|
Pneumocystis jiroveci pneumonia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Current therapies for PCP, such as trimethoprim-sulfamethoxazole (TMP-SMX), suffer from significant treatment failures and a multitude of serious side effects.Novel therapeutic approaches (i.e. newly developed drugs or novel combinations of available drugs) are needed to treat this potentially lethal opportunistic infection.
|
30016951 |
2018 |
|
Pneumocystis jiroveci pneumonia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Especially with the long-term use of trimethoprim-sulfamethoxazole (TMP-SMX) and dapsone, certain point mutations in the Pneumocystis jirovecii (P. jirovecii) dihydropteroate synthase (DHPS) gene are known to play an important role in the development of resistance.
|
30027382 |
2018 |
|
Pneumocystis jiroveci pneumonia
|
0.100 |
Biomarker
|
disease |
BEFREE |
TMP-SMX prophylaxis significantly reduces the PCP incidence with a favourable safety profile in patients with rheumatic disease receiving prolonged, high-dose steroids.
|
29092853 |
2018 |
|
Pneumocystis jiroveci pneumonia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Trimethoprim-sulfamethoxazole (TMP-SMX) is the first line regimen for Pneumocystis jirovecii pneumonia.
|
30575940 |
2018 |
|
Pneumocystis jiroveci pneumonia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chemoprophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX) is highly effective in preventing PJP in both HIV-positive and -seronegative patients.
|
28035717 |
2017 |
|
Pneumocystis jiroveci pneumonia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The twice-longer duration of mechanical ventilation in patients with mutant DHPS genotypes suggests a decreased efficacy of TMP-SMX and warrants collaborative studies to assess the relevance of DHPS mutations and further research to increase therapeutic options for PCP.
|
27855071 |
2017 |
|
Pneumocystis jiroveci pneumonia
|
0.100 |
Biomarker
|
disease |
BEFREE |
To the best of our knowledge, this is the first case of TMP-SMX-resistant PCP described in Korea.
|
26174826 |
2015 |
|
Pneumocystis jiroveci pneumonia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to investigate the incidence of hepatotoxicity and the role of concomitant use of fluconazole in HIV-infected patients receiving TMP/SMX for Pneumocystis jirovecii pneumonia.
|
25184238 |
2014 |
|
Pneumocystis jiroveci pneumonia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite alteration of treatment secondary to the development of allergic reaction to trimethoprim-sulfamethoxazole (TMP-SMX), the patient was able to complete a 3-week therapy for PCP after being switched to pentamidine isetionate.
|
21249414 |
2011 |